JP2008514577A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514577A5 JP2008514577A5 JP2007532963A JP2007532963A JP2008514577A5 JP 2008514577 A5 JP2008514577 A5 JP 2008514577A5 JP 2007532963 A JP2007532963 A JP 2007532963A JP 2007532963 A JP2007532963 A JP 2007532963A JP 2008514577 A5 JP2008514577 A5 JP 2008514577A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- imatinib
- acceptable salt
- warm
- man
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 11
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 10
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 10
- 229960002411 imatinib Drugs 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 241001465754 Metazoa Species 0.000 claims 9
- 230000005865 ionizing radiation Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000001772 anti-angiogenic effect Effects 0.000 claims 3
- 230000001603 reducing effect Effects 0.000 claims 3
- 230000008728 vascular permeability Effects 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0421438A GB0421438D0 (en) | 2004-09-27 | 2004-09-27 | Combination therapy |
| GB0506726A GB0506726D0 (en) | 2005-04-01 | 2005-04-01 | Combination therapy |
| PCT/GB2005/003673 WO2006035204A2 (en) | 2004-09-27 | 2005-09-23 | Combination comprising zd6474 and an imatinib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008514577A JP2008514577A (ja) | 2008-05-08 |
| JP2008514577A5 true JP2008514577A5 (enExample) | 2008-08-28 |
Family
ID=35924044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007532963A Pending JP2008514577A (ja) | 2004-09-27 | 2005-09-23 | Ｚｄ６４７４及びイマチニブを含んでなる組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20080119479A1 (enExample) |
| EP (1) | EP1804802A2 (enExample) |
| JP (1) | JP2008514577A (enExample) |
| KR (1) | KR20070072543A (enExample) |
| AU (1) | AU2005288737B2 (enExample) |
| BR (1) | BRPI0516052A (enExample) |
| CA (1) | CA2578956A1 (enExample) |
| IL (1) | IL181609A0 (enExample) |
| MX (1) | MX2007003505A (enExample) |
| NO (1) | NO20071428L (enExample) |
| WO (1) | WO2006035204A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| CA2514227C (en) * | 2003-02-13 | 2011-08-09 | Astrazeneca Ab | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| AU2004255022B2 (en) * | 2003-07-10 | 2007-08-23 | Astrazeneca Ab | Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| SI1971338T1 (sl) * | 2005-12-22 | 2011-06-30 | Astrazeneca Ab | Kombinacija ZD6474 in pemetrekseda |
| EP2066353B1 (en) * | 2006-09-29 | 2013-01-02 | AstraZeneca AB | Combination of zd6474 and bevacizumab for cancer therapy |
| EP2252955A1 (en) | 2008-03-03 | 2010-11-24 | Nike International Ltd. | Interactive athletic equipment system |
| US8628453B2 (en) | 2008-12-05 | 2014-01-14 | Nike, Inc. | Athletic performance monitoring systems and methods in a team sports environment |
| US20100184564A1 (en) | 2008-12-05 | 2010-07-22 | Nike, Inc. | Athletic Performance Monitoring Systems and Methods in a Team Sports Environment |
| US8231506B2 (en) | 2008-12-05 | 2012-07-31 | Nike, Inc. | Athletic performance monitoring systems and methods in a team sports environment |
| EP2638491B1 (en) | 2010-11-10 | 2022-10-05 | NIKE Innovate C.V. | Systems and methods for time-based athletic activity measurement and display |
| KR20140004205A (ko) | 2011-02-17 | 2014-01-10 | 나이키 인터내셔널 엘티디. | 위치 맵핑 |
| KR101386697B1 (ko) | 2012-06-18 | 2014-04-18 | 아주대학교산학협력단 | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
| US20150044288A1 (en) | 2013-07-31 | 2015-02-12 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
| KR101778004B1 (ko) | 2015-06-22 | 2017-09-15 | (주) 에빅스젠 | 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물 |
| US11957681B2 (en) | 2017-07-26 | 2024-04-16 | Shorla Pharma Limited | Liquid dosage forms of Imatinib |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU229414B1 (hu) * | 1999-11-05 | 2013-12-30 | Astrazeneca Ab | Kinazolin-származékok mint VEGF-inhibitorok, eljárás az elõállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| AU2003231098A1 (en) * | 2002-04-25 | 2003-11-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| MXPA05001458A (es) * | 2002-08-09 | 2005-06-06 | Astrazeneca Ab | Combinacion de zd6474, un inhibidor del receptor del factor de crecimiento endotelial vascular, con radioterapia en tratamiento de cancer. |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| CA2514227C (en) * | 2003-02-13 | 2011-08-09 | Astrazeneca Ab | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
| AU2004255022B2 (en) * | 2003-07-10 | 2007-08-23 | Astrazeneca Ab | Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| WO2006035203A1 (en) * | 2004-09-27 | 2006-04-06 | Astrazeneca Ab | Cancer combination therapy comprising azd2171 and imatinib |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| SI1971338T1 (sl) * | 2005-12-22 | 2011-06-30 | Astrazeneca Ab | Kombinacija ZD6474 in pemetrekseda |
-
2005
- 2005-09-23 WO PCT/GB2005/003673 patent/WO2006035204A2/en not_active Ceased
- 2005-09-23 JP JP2007532963A patent/JP2008514577A/ja active Pending
- 2005-09-23 AU AU2005288737A patent/AU2005288737B2/en not_active Ceased
- 2005-09-23 BR BRPI0516052-9A patent/BRPI0516052A/pt not_active IP Right Cessation
- 2005-09-23 US US11/663,913 patent/US20080119479A1/en not_active Abandoned
- 2005-09-23 KR KR1020077009369A patent/KR20070072543A/ko not_active Withdrawn
- 2005-09-23 EP EP05786268A patent/EP1804802A2/en not_active Withdrawn
- 2005-09-23 CA CA002578956A patent/CA2578956A1/en not_active Abandoned
- 2005-09-23 MX MX2007003505A patent/MX2007003505A/es not_active Application Discontinuation
-
2007
- 2007-02-27 IL IL181609A patent/IL181609A0/en unknown
- 2007-03-16 NO NO20071428A patent/NO20071428L/no not_active Application Discontinuation
-
2009
- 2009-06-05 US US12/479,131 patent/US20100069398A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008514577A5 (enExample) | ||
| JP2006504723A5 (enExample) | ||
| JP2006500346A5 (enExample) | ||
| JP2005511597A5 (enExample) | ||
| CA2531862A1 (en) | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| CA2501651A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| JP2015523397A5 (enExample) | ||
| JP2020514311A5 (enExample) | ||
| JP2012521435A5 (enExample) | ||
| JP2013509444A5 (enExample) | ||
| JP2006507308A5 (enExample) | ||
| CA2464758A1 (en) | Combination therapy comprising zd6474 and a taxane | |
| JP2017519019A5 (enExample) | ||
| JP2006502132A5 (enExample) | ||
| JP2011503063A5 (enExample) | ||
| JP2015502926A5 (enExample) | ||
| JP2013541583A5 (enExample) | ||
| JP2012522841A5 (enExample) | ||
| JP2009539994A5 (enExample) | ||
| JP2015507020A5 (enExample) | ||
| JP2014512355A5 (enExample) | ||
| JP2018522028A5 (enExample) | ||
| JP2014530181A5 (enExample) | ||
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use |